|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||99.06 - 100.31|
|52 Week Range||75.81 - 106.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Spark Therapeutics, Rite Aid, and Alnylam Pharmaceuticals shares have dropped recently, but that doesn't necessarily make all three stocks worth buying.
Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.
Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.
To trade momentum biotech stocks, it's often best to follow the top experts. Using TipRanks' Top-Rated Stocks investor tool, we can see which biotech names float as Wall Street's most recommended stocks today.
Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.
In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.
Spark Therapeutics crashed Tuesday after its hemophilia A study results seemingly lagged a rival treatment from BioMarin Pharmaceutical. Spark plunged 27.8% in high volume.
Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.
On August 7, Jazz Pharmaceuticals (JAZZ) released its second-quarter 2018 financial results. Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.
Ionis Pharmaceuticals (IONS), one of the leading biopharmaceutical companies, is focused on developing RNA-targeted therapies. Ionis has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. Ionis missed Wall Street analyst estimates and reported earnings per share of -$0.29 on revenues of $117.7 million during Q2 2018 as compared to EPS estimates of -$0.09 on revenues of $135.5 million during the quarter.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on Aug. 7) Akcea Therapeutics Inc (NASDAQ: AKCA )(reacted to Q2 earnings ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding BMRN is favorable, with net inflows of $17.81 billion.
Biotechnology investors are no strangers to volatility, and Tuesday's price action was no exception. Followers of gene therapy companies watched one of the most popular names in the industry lose approximately one-third of its value due to patient safety concerns. As alluded to above, shares of Spark Therapeutics dropped sharply in Tuesday's trading session due to heightened patient safety concerns surrounding a hemophilia gene therapy trial.
Stifel updated its outlook on the biotech sector, and sees reason to be bullish on several big names. While biotech has had its ups and downs, in general this has been a good year to be in the sector: The iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have risen 10.7% and 12.8%, respectively, since the start of 2018, above the broader market and even the gain seen by the increasing popular health-care sector itself, as the Health Care Select Sector SPDR ETF (XLV) is up 8.8% since the start of the year. While smaller biotechs have benefited more from the moves, there are still some bigger companies that warrant attention, argues Stifel's Paul Matteis. Stifel transferred and initiated coverage on a number of biotech stocks, today, with Buy ratings on Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceuticals (BMRN), Biogen (BIIB), Alnylam Pharmaceuticals (ANLY), Sage Therapeutics (SAGE), Neurocrine Biosciences (NBIX), Wave Life Sciences (WVE), and Alder BioPharmaceuticals (ALDR).
BeiGene (BGNE) reported revenues of $32.5 million and EPS of -$2.03 in the first quarter. Analysts expect BeiGene to report EPS of -$2.06 on revenues of $22.5 million during the second quarter. This represents 100.0% growth in its YoY (year-over-year) revenues, compared to zero revenues during the second quarter of 2017. The chart below compares analysts’ recommendations over the last 12 months.
Spark Therapeutics Inc. (ONCE) shares dropped 28% in Tuesday premarket trade after the company said two patients in its hemophilia phase 1/2 trial had a concerning immune response, one of whom was hospitalized as a result. Twelve patient total have been dosed so far in the clinical trial, which is testing the company's gene therapy SPK-9001 in patients with hemophilia B, and the therapy's effect on patients' clotting factor levels was an important outcome.
Spark Therapeutics says its experimental treatment for hemophilia A reduced bleeds and the need for therapeutic infusions by 97 percent in a trial of 12 patients. Investors were disappointed by the results and sent the shares plunging by as much as 32 percent before the market opened. Shares of biotechnology company Spark Therapeutics ONCE slid more than 30 percent in premarket trading Tuesday after the company reported the results of a small trial for an experimental gene therapy treatment for hemophilia that reduced bleeds in most patients but sent one to the hospital.
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.